Zenith presented this morning at BIO-Europe. Slides are here. 

Sounds like the mCRPC combo trial is still going strong. From the language used in the presentation, it sounds like the ZEN-3694 + enzalutamide combo is working better in abiraterone progressors than it is in enzalutamide progressors. The combo seems to have some clinical activity in both cohorts, but for the abiraterone progressors the slides indicate "Significant response in primary abiraterone progressors (rPFS and PSA)......Extending time on therapy well beyong the SOC." But the data for the enzalutamide progressors is described as only "Promising Data." The enzalutamide progressor cohort hasn't been tested for as long as the abiraterone cohort, so maybe just more patients and patience are needed.

Interesting statement on slide 14 "Clinical data to be presented at American Association for Cancer Research 2019. Zenith will be the first to release clinical combination data with a BETi at a major scientific meeting." That AACR presentation is coming up on April 1. Honestly, I have a hard time interpreting the data presented in Zenith corporate updates and have difficulty putting it into context of current standard of care expectations for mCRPC. Hopefully the AACR presentation is posted and provides much better scientific/clinical context, results description, and results interpretation.

Some good details of the upcoming ZEN-3694/PARPi combo trial with Pfizer for TNBC on slide 19. No start date mentioned and nothing on ClinicalTrials.gov yet. 

BearDownAZ